Posted by Michael Wonder on 20 Jul 2017
Leo Pharma receives marketing authorisation for Kyntheum (brodalumab), a new biologic for the treatment of moderate-to-severe plaque psoriasis in the European Union
20 July 2017 - Leo Pharma today announced that the European Commission has granted marketing authorisation for Kyntheum (brodalumab), a new biologic for the treatment of moderate-to-severe plaque psoriasis in adults within the European Union who are candidates for systemic therapy.
Kyntheum is the first and only biologic that selectively targets the IL-17 receptor subunit A.2.
